Loading stock data…
Valneva SE (VALN)
$5.17-0.02 (-0.39%)
Market ClosedLast close Jun 29
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Valneva SE in the Healthcare sector is trading at $5.17 with a market capitalization of $507M. Wall Street consensus targets $12.20 (4 analysts), implying a +136.0% move over the next 12 months. The stock is currently near its 52-week low of $5.04, remaining 38.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +136.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $30.90M↓ | $47.69M↑ | $29.41M↓ | $48.33M↓ | $49.23M |
| Gross Profit | $4.72M↓ | $11.62M↑ | $5.50M↓ | $24.21M↓ | $26.19M |
| Operating Income | -$23.70M↑ | -$27.68M↑ | -$37.35M↓ | -$10.64M↓ | -$5.96M |
| Net Income | -$32.07M↑ | -$50.02M↓ | -$44.35M↓ | -$11.59M↓ | -$9.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$507.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-179.97%
Volume
Today's trading volume
36,693
Recent News
Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...
Valneva SE (INRLF) showcases strong vaccine progress but faces hurdles with declining sales and operational losses.
Valneva Q1 Earnings Call Highlights
Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach
Transcript: Valneva Q1 2026 Earnings Conference Call
On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous
Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13
Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy rating on the shares. The firm adjusted estimates on the stock as part of a fiscal Q1 earnings preview for the commercial stage […]
Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data
Valneva SE (NASDAQ:VALN) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405. Jefferies said that the stock reaction […]